Sales of Actinum series have been sluggish

In the first half of this year, 200 million won worth of appearance

Expect blockbusters as the main characters of the once high-content vitamin

The reason for the sluggishness is the boycott of No Japan and direct management of copyrights

The Actinum series, once known as Takeda Pharmaceutical's signature mixed vitamin, is experiencing its biggest sales slump in more than seven years since its launch.

 

According to drug distribution performance data, the performance of the Actinium series last year was 2.3 billion won, down 74% from 8.9 billion won in 2018.

 

Between 2018 and 2021, Actinium EX Gold's sales were 4 billion, 2.9 billion, 1.5 billion, and 990 million won, and Actinium EX Gold recorded 4.9 billion, 3.7 billion, 2.1 billion, and 1.2 billion won during the same period.

 

In the first half of 2022, the appearance of the two products was 140 million won and 80 million won, respectively, the worst in the past five years.

 

Actinum, whose main ingredient is Fursultiamine, is once expected to be a blockbuster OTC drug through two lineup of EX Gold and Plus, and is considered the main player in the so-called high-dosage vitamin drug.

 

The inflection point of performance is the aftermath of the boycott of No Japan in 2019 and Takeda, which ended this yearIt is in line with the issue of the transfer rights.

 

It is analyzed that the performance has drawn a gradual downward curve in the indiscriminate boycott of Japanese products, regardless of all industries such as pharmaceuticals, automobiles, and food and beverage.

 

Takeda Pharmaceutical recently transferred its license to Celltrion Pharmaceutical for its OTC Whituben and Albotyl.

 

Actinum is known to have handed over its copyright to Japanese company Alinamin Pharma in 2021.

 

Actinium, which was launched in Korea in 2015, has been sold through cooperative wholesalers such as Geo-Young and Dongwon, and signed an exclusive domestic sales partnership contract with Dong-Wha from April 2019 to January this year.

 

Currently, the authority to import and sell Actinium is in charge of ZP Therapeutics Korea, a commercial business corporation of Zuellig Pharma Korea.

 

The rapid success factor of this product, which was renamed Arinamin in Japan and marketed as Actinum in Korea, lies in its product power.

 

Actinium is a thin-layer sugar tablet and manufacturing method patent, which increases the convenience of taking vitamins with a small size of 9.2mm, and the content and ingredients are stable for four years with a stabilized vitamin product patent.

 

According to Actinium clinical studies, about 80% of patients complaining of eye fatigue, shoulder stiffness, and back pain showed mild or higher symptoms, and at least 3.3 days to up to 5.9 days after starting to take each symptom.

 

In recognition of these efficacy, Actinium EX Plus passed Seoul National University Hospital's Drug Committee (DC) three months after its launch in August 2015, and its product power was recognized.

 

In particular, sufficient data such as clinical data must be available to pass OTC DC at Seoul National University Hospital.

 

In fact, OTC landed at Seoul National University Hospital is only a small number of items such as Ildong's Aronamin and Pfizer's Centrum.